| ［1］ |
鞠强. 中外痤疮指南药物治疗之亮点［J］. 中华皮肤科杂志, 2017,50（6）:459⁃462. doi: 10.3760/cma.j.issn.0412⁃4030.2017. 06.024.
|
| ［2］ |
Cong TX, Hao D, Wen X, et al. From pathogenesis of acne vulgaris to anti⁃acne agents［J］. Arch Dermatol Res, 2019,311（5）:337⁃349. doi: 10.1007/s00403⁃019⁃01908⁃x.
|
| ［3］ |
Zhanel G, Critchley I, Lin LY, et al. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris［J］. Antimicrob Agents Chemother, 2019,63（1）:e01297⁃18. doi: 10.1128/AAC.01297⁃18.
|
| ［4］ |
Moore A, Green LJ, Bruce S, et al. Once⁃daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double⁃blind clinical trials［J］. J Drugs Dermatol, 2018,17（9）:987⁃996.
|
| ［5］ |
Asadi A, Abdi M, Kouhsari E, et al. Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: back to the future［J］. J Glob Antimicrob Resist, 2020,22:161⁃174. doi: 10.1016/j.jgar.2020.01.022.
|
| ［6］ |
Dosik J, Ellman H, Stuart I. Topical minocycline foam 4%: results of four phase 1 studies evaluating the potential for phototoxicity, photoallergy, sensitization, and cumulative irritation［J］. J Immunotoxicol, 2019,16（1）:133⁃139. doi: 10. 1080/1547691X.2019.1610117.
|
| ［7］ |
Gold LS, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderate⁃to⁃severe acne vulgaris: results of 2 randomized, double⁃blind, phase 3 studies［J］. J Am Acad Dermatol, 2019,80（1）:168⁃177. doi: 10.1016/j.jaad.2018. 08.020.
|
| ［8］ |
Raoof TJ, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study［J］. J Am Acad Dermatol, 2020,82（4）:832⁃837. doi: 10.1016/j.jaad.2019.05.078.
|
| ［9］ |
Yin S, Luo J, Qian A, et al. Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity［J］. J Clin Invest, 2013,123（9）:3941⁃3951. doi: 10.1172/JCI66413.
|
| ［10］ |
Aubert J, Piwnica D, Bertino B, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor⁃γ agonist trifarotene［J］. Br J Dermatol, 2018,179（2）:442⁃456. doi: 10.1111/bjd.16719.
|
| ［11］ |
Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne［J］. J Am Acad Dermatol, 2019,80（6）:1691⁃1699. doi: 10.1016/j.jaad.2019.02.044.
|
| ［12］ |
Blume⁃Peytavi U, Fowler J, Kemény L, et al. Long⁃term safety and efficacy of trifarotene 50 μg/g cream, a first⁃in⁃class RAR⁃γ selective topical retinoid, in patients with moderate facial and truncal acne［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:166⁃173. doi: 10.1111/jdv.15794.
|
| ［13］ |
Ju Q, Tao T, Hu T, et al. Sex hormones and acne［J］. Clin Dermatol, 2017,35（2）:130⁃137. doi: 10.1016/j.clindermatol.2016. 10.004.
|
| ［14］ |
Park JH, Bienenfeld A, Orlow SJ, et al. The use of hormonal antiandrogen therapy in female patients with acne: a 10⁃year retrospective Study［J］. Am J Clin Dermatol, 2018,19（3）:449⁃455. doi: 10.1007/s40257⁃018⁃0349⁃6.
|
| ［15］ |
Rosette C, Agan FJ, Mazzetti A, et al. Cortexolone 17α⁃propionate （clascoterone） is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro［J］. J Drugs Dermatol, 2019,18（5）:412⁃418.
|
| ［16］ |
Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials［J］. JAMA Dermatol, 2020,156（6）:621⁃630. doi: 10.1001/jamadermatol. 2020.0465.
|
| ［17］ |
Eichenfield L, Hebert A, Gold LS, et al. Open⁃label, long⁃term extension study to evaluate the safety of clascoterone （CB⁃03⁃01） cream, 1% twice daily, in patients with acne vulgaris［J］. J Am Acad Dermatol, 2020,83（2）:477⁃485. doi: 10.1016/j.jaad. 2020.04.087.
|
| ［18］ |
Keating GM. Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years［J］. Am J Clin Dermatol, 2011,12（6）:407⁃420. doi: 10.2165/11208170⁃000000000⁃00000.
|
| ［19］ |
Seidler EM, Kimball AB. Meta⁃analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne［J］. J Am Acad Dermatol, 2010,63（1）:52⁃62. doi: 10.1016/j.jaad.2009.07.052.
|
| ［20］ |
Amar L, Kircik LH. Treatment of moderate acne vulgaris in fitzpatrick skin type Ⅴ or Ⅵ: efficacy and tolerability of fixed combination clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel［J］. J Drugs Dermatol, 2018,17（10）:1107⁃1112.
|
| ［21］ |
Zouboulis CC, Fischer TC, Wohlrab J, et al. Study of the efficacy, tolerability, and safety of 2 fixed⁃dose combination gels in the management of acne vulgaris［J］. Cutis, 2009,84（4）:223⁃229.
|
| ［22］ |
Weiss J, Stein Gold L, Leoni M, et al. Customized single⁃agent therapy management of severe inflammatory acne: a randomized, double⁃blind, parallel⁃group, controlled study of a new treatment⁃⁃adapalene 0.3%⁃benzoyl peroxide 2.5% gel［J］. J Drugs Dermatol, 2015,14（12）:1427⁃1435.
|
| ［23］ |
Gold MH, Baldwin H, Lin T. Management of comedonal acne vulgaris with fixed⁃combination topical therapy［J］. J Cosmet Dermatol, 2018,17（2）:227⁃231. doi: 10.1111/jocd.12497.
|
| ［24］ |
Ghaoui N, Hanna E, Abbas O, et al. Update on the use of dapsone in dermatology［J］. Int J Dermatol, 2020,59（7）:787⁃795. doi: 10.1111/ijd.14761.
|
| ［25］ |
Stein Gold LF, Jarratt MT, Bucko AD, et al. Efficacy and safety of once⁃daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle⁃controlled trials［J］. J Drugs Dermatol, 2016,15（5）:553⁃561.
|
| ［26］ |
Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once⁃daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle⁃controlled trials［J］. J Drugs Dermatol, 2016,15（8）:962⁃969.
|
| ［27］ |
Jarratt MT, Jones TM, Chang⁃Lin JE, et al. Safety and pharmacokinetics of once⁃daily dapsone gel, 7.5% in Patients With Moderate Acne Vulgaris［J］. J Drugs Dermatol, 2016,15（10）:1250⁃1259.
|
| ［28］ |
Yale S, Stefanko N, McCarthy P, et al. Severe methemoglobinemia due to topical dapsone misuse in a teenage girl［J］. Pediatr Dermatol, 2020,37（2）:377⁃378. doi: 10.1111/pde.14080.
|
| ［29］ |
Jones ML, Ganopolsky JG, Labbé A, et al. Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices［J］. Appl Microbiol Biotechnol, 2010,88（2）:401⁃407. doi: 10.1007/s00253⁃010⁃2733⁃x.
|
| ［30］ |
Qin M, Landriscina A, Rosen JM, et al. Nitric oxide⁃releasing nanoparticles prevent propionibacterium acnes⁃induced inflammation by both clearing the organism and inhibiting microbial stimulation of the innate immune response［J］. J Invest Dermatol, 2015,135（11）:2723⁃2731. doi: 10.1038/jid. 2015.277.
|
| ［31］ |
Hebert A,Del Rosso J, Rico M, et al.Evaluation of the efficacy, safety and tolerability of SB204 4% once⁃daily in subjects with moderate to severe acne vulgaris treated topically for up to 52 weeks ［R/OL］//American Academy of Dermatology （AAD） Annual Meeting, San Diego, 2018［2020⁃06⁃01］. http: //novan.com/files/3115/1913/6178/SB204_Phase_3_AAD_Latebreaker_Presentation_vf.pdf.
|
| ［32］ |
Melnik BC. Olumacostat glasaretil, a promising topical sebum⁃suppressing agent that affects all major pathogenic factors of acne vulgaris［J］. J Invest Dermatol, 2017,137（7）:1405⁃1408. doi: 10.1016/j.jid.2017.01.026.
|
| ［33］ |
Dermira, Inc. Dermira′s two phase 3 trials evaluating olumacostat glasaretil in patients with acne vulgaris did not meet co⁃ primary endpoints ［EB/OL］. （2018⁃03⁃05）［2020⁃06⁃01］. https://investor.dermira.com/news⁃releases/press⁃release⁃details/2018/Dermiras⁃Two⁃Phase⁃3⁃Trials⁃Evaluating⁃Olumacostat⁃Glasaretil⁃in⁃Patients⁃with⁃Acne⁃Vulgaris⁃Did⁃Not⁃Meet⁃Co⁃Primary⁃Endpoints/default.aspx.
|
| ［34］ |
Valente Duarte De Sousa IC. New and emerging drugs for the treatment of acne vulgaris in adolescents［J］. Expert Opin Pharmacother, 2019,20（8）:1009⁃1024. doi: 10.1080/14656566. 2019.1584182.
|
